Orforglipron Results: Weight Loss Trumps Novos Rybelsus by a Wide Margin The results Lilly recently released tested orforglipron on patients with type 2 diabetes
Ozempic, which uses the active ingredient semaglutide, was approved in the US for diabetes in 2017 and subsequently in the UK, and its counterpart for weight loss, Wegovy, was approved in the US in 2021
Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences
Any adverse effects from GLP-1 medicationsincluding persistent nausea, vomiting, abdominal pain, or signs of pancreatitisshould prompt immediate contact with a healthcare professional, regardless of how the medication was obtained
While we do have an in-person clinic in Danville, we also offer full telehealth consultations
Ozempic Lawsuit Update As of 2025, the Ozempic lawsuit continues to gain momentum, with hundreds of claims consolidated into a federal multidistrict litigation (MDL) in the Eastern District of Pennsylvania